Skip to content

Study · Systematic review · 2025

5 results

Discontinuing glucagon-like peptide-1 receptor agonists and body habitus: A systematic review and meta-analysis.

Berg S, Stickle H, Rose SJ, Nemec EC

Obesity reviews : an official journal of the International Association for the Study of Obesity4 Apr 2025Cited by 62 (Europe PMC)

PMID40186344 (opens in a new tab)DOI10.1111/obr.13929 (opens in a new tab)PepBankPUB-40186344
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In adults with overweight or obesity, participants who stopped liraglutide regained a pooled mean of 2.20 kg.

    In plain wordsIn adults with overweight or obesity, people regained 2.20 kg on average after stopping liraglutide.

    Peptide
    Liraglutide
    Outcome
    IncreaseWeight regain after discontinuation
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    weight regain
    2.2 kg
    liraglutide

    Source sentences

    Summary
    Participants who took liraglutide regained 2.20 kg (95% CI 1.69 to 2.70, P < 0.00001
    1 context sentence
    Summary · context
    ResultsThe initial search yielded 497 relevant articles and, after screening, retained 8 randomized controlled trials comprised of 2372 participants, all with a BMI ≥ 27 kg/m2.

Studies that did not test the peptide alone4

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

  1. 02HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome

    In adults with a BMI of 27 kg/m2 or more, pooled data showed 9.69 kg of weight regain after discontinuing semaglutide or tirzepatide.

    In plain wordsIn adults with overweight or obesity, people regained about 9.69 kg on average after they stopped semaglutide or tirzepatide.

    Peptide
    Tirzepatide
    Outcome
    IncreaseWeight regain after stopping semaglutide/tirzepatide
    Study

    n: not reported in source

    Comparator
    Weight on treatment
    Outcome group
    Body weight · Metabolic and weight

    Measurements

    Weight regain
    9.69 kg
    semaglutide/tirzepatide, off treatment

    Source sentences

    Summary
    participants taking semaglutide/tirzepatide regained 9.69 kg (95% CI 5.78 to 13.60, P < 0.00001)
    1 context sentence
    Summary · context
    ResultsThe initial search yielded 497 relevant articles and, after screening, retained 8 randomized controlled trials comprised of 2372 participants, all with a BMI ≥ 27 kg/m2.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

  2. 03HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome

    In adults with overweight or obesity, participants who stopped semaglutide or tirzepatide (pooled) regained a mean of 9.69 kg.

    In plain wordsIn adults with overweight or obesity, people regained 9.69 kg on average after stopping semaglutide or tirzepatide, pooled together.

    Peptide
    Semaglutide
    Outcome
    IncreaseWeight regain after discontinuation, semaglutide/tirzepatide
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight

    Measurements

    weight regain
    9.69 kg
    semaglutide/tirzepatide pooled

    Source sentences

    Summary
    and participants taking semaglutide/tirzepatide regained 9.69 kg (95% CI 5.78 to 13.60, P < 0.00001).
    1 context sentence
    Summary · context
    ResultsThe initial search yielded 497 relevant articles and, after screening, retained 8 randomized controlled trials comprised of 2372 participants, all with a BMI ≥ 27 kg/m2.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  3. 04HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome

    After stopping GLP-1 receptor agonists (including liraglutide), weight regain was proportional to the original weight loss.

    In plain wordsIn adults who stopped GLP-1 drugs, including liraglutide, the weight they regained matched how much they had first lost.

    Peptide
    Liraglutide
    Outcome
    IncreaseWeight regain relative to original weight loss
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    After discontinuing GLP-1RA therapy, weight regain was proportional to the original weight loss.
    1 context sentence
    Summary · context
    ResultsThe initial search yielded 497 relevant articles and, after screening, retained 8 randomized controlled trials comprised of 2372 participants, all with a BMI ≥ 27 kg/m2.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  4. 05HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome

    After stopping GLP-1 receptor agonists (including semaglutide), weight regain was proportional to the original weight loss.

    In plain wordsIn adults who stopped GLP-1 drugs, including semaglutide, the weight they regained matched how much they had first lost.

    Peptide
    Semaglutide
    Outcome
    IncreaseWeight regain relative to original weight loss
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    After discontinuing GLP-1RA therapy, weight regain was proportional to the original weight loss.
    1 context sentence
    Summary · context
    ResultsThe initial search yielded 497 relevant articles and, after screening, retained 8 randomized controlled trials comprised of 2372 participants, all with a BMI ≥ 27 kg/m2.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Versions 4 to 39Current

    28 Oct 2026, 02:04 UTC

    The same notice was added 36 times, first on 9 Oct 2026, 19:08 UTC. The status did not change between them.

    Study results updated

  2. Versions 2 to 3

    9 Oct 2026, 03:07 UTC

    The same notice was added 2 times, first on 9 Oct 2026, 03:06 UTC. The status did not change between them.

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.